Last reviewed · How we verify
GIP infusion
At a glance
| Generic name | GIP infusion |
|---|---|
| Sponsor | David D'Alessio, M.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies (PHASE4)
- The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes (NA)
- Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion (NA)
- GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension (NA)
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese (PHASE2)
- Beta-cell Response to Incretin Hormones in Cystic Fibrosis (NA)
- Splanchnic Venous Capacitance in Postural Tachycardia Syndrome (PHASE2)
- Testing the Potential Metabolic Effect of the Human Gut Bacterial Peptide, RUCILP, in Healthy Men (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GIP infusion CI brief — competitive landscape report
- GIP infusion updates RSS · CI watch RSS
- David D'Alessio, M.D. portfolio CI